Frédéric Bérard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Frédéric Bérard has a total of 526 co-authors. Here are the top co-authors by number of shared publications:
- Jean-François Nicolas
CIRI (Centre International de Recherche en Infectiologie), INSERM, U1111, Univ Lyon, Université de Lyon 1, Ecole Normale Supérieure de Lyon, CNRS, UMR 5308, Lyon, France
78 shared publications - Audrey Nosbaum
Hospices Civils de Lyon, South of Lyon Hospital, Allergology and Clinical Immunology Department, Pierre-Bénite, France
41 shared publications - Aurore Rozières
Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Université Lyon 1, Inserm U1111, CNRS UMR5308, ENS de Lyon, 69007 Lyon, France
18 shared publications - Florence Hacard
Service d'Allergologie et d'Immunologie Clinique Hôpital Lyon‐Sud, Hospices Civils de Lyon, Inserm U1111 CIRI Pierre‐Bénite France
12 shared publications H Perrot
11 shared publications- Marc Vocanson
Centre International de Recherche en Infectiologie University of Lyon 1 and École Normale Supérieure de Lyon, Inserm U1111 Lyon France
9 shared publications
Latest Publications
- Open Access
SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.
Open AccessSARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.
- 2 April 2021
- Published by Wiley in Contact Dermatitis
- Vol. 85 (2) , 265-266
Molecular analysis of an intradermal skin test to establish the diagnosis of delayed allergy to paclitaxel
- 2 April 2021
- Published by Wiley in Contact Dermatitis
- Vol. 85 (2) , 265-266
Molecular analysis of an intradermal skin test to establish the diagnosis of delayed allergy to paclitaxel
- 1 March 2019
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 40 (3) , 166-172
Urticaire aux AINS : une prise en charge similaire à celle de l’urticaire aiguë
- 1 March 2019
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 40 (3) , 166-172
Urticaire aux AINS : une prise en charge similaire à celle de l’urticaire aiguë
- 3 December 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 83 (3) , 425-430
Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) shows encouraging results for patients with unresectable peritoneal metastasis. Several reports demonstrated the safety of the procedure combined with systemic chemotherapy, with a low rate of complication. The aim of this study is to report severe hypersensitivity reactions to platinum compounds (SHRPC) during PIPAC procedures.
- 3 December 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 83 (3) , 425-430
Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) shows encouraging results for patients with unresectable peritoneal metastasis. Several reports demonstrated the safety of the procedure combined with systemic chemotherapy, with a low rate of complication. The aim of this study is to report severe hypersensitivity reactions to platinum compounds (SHRPC) during PIPAC procedures.
- 21 August 2018
- Published by S. Karger AG in Digestive Diseases
- Vol. 36 (6) , 417-426
Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions
Background and Aims: One of the reasons for the failure of infliximab (IFX) is immediate hypersensitivity reactions (IHR). We aimed to report the efficacy and safety of a tolerance induction protocol in inflammatory bowel diseases (IBD) patients who had previously experienced IHR during IFX infusions. Patients and Methods: We reported all cases of IBD patients who had previously experienced IHR due to IFX and who were submitted to a standardized protocol of tolerance induction to IFX from 2010 to 2015. Results: IHR occurred in a majority of patients (69%) during the first 3 infusions and for half of them after a period of IFX withdrawn. Skin prick tests were negative and only 2 intradermal tests were positive. Basophil activation tests and antidrug antibody measurements were performed in 8 out of 16 patients and were positive in 3 and 4 patients respectively. Induction of tolerance was successful in 69% of patients and IFX was pursued with clinical efficacy > 1 year in 7 patients (44%). Allergologic investigations were not predictive of tolerance induction success. Conclusion: A majority of IHR to IFX infusions occurred during the beginning or restarting of treatment and was related to a nonallergic hypersensitivity. Induction of tolerance to IFX is feasible and effective and may safely allow retreatment of IFX in almost 70% of IBD patients.
- 21 August 2018
- Published by S. Karger AG in Digestive Diseases
- Vol. 36 (6) , 417-426
Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions
Background and Aims: One of the reasons for the failure of infliximab (IFX) is immediate hypersensitivity reactions (IHR). We aimed to report the efficacy and safety of a tolerance induction protocol in inflammatory bowel diseases (IBD) patients who had previously experienced IHR during IFX infusions. Patients and Methods: We reported all cases of IBD patients who had previously experienced IHR due to IFX and who were submitted to a standardized protocol of tolerance induction to IFX from 2010 to 2015. Results: IHR occurred in a majority of patients (69%) during the first 3 infusions and for half of them after a period of IFX withdrawn. Skin prick tests were negative and only 2 intradermal tests were positive. Basophil activation tests and antidrug antibody measurements were performed in 8 out of 16 patients and were positive in 3 and 4 patients respectively. Induction of tolerance was successful in 69% of patients and IFX was pursued with clinical efficacy > 1 year in 7 patients (44%). Allergologic investigations were not predictive of tolerance induction success. Conclusion: A majority of IHR to IFX infusions occurred during the beginning or restarting of treatment and was related to a nonallergic hypersensitivity. Induction of tolerance to IFX is feasible and effective and may safely allow retreatment of IFX in almost 70% of IBD patients.
- Open Access
Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU
Background: ASSURE‐CSU revealed differences in physician and patient reporting of angioedema. This post hoc analysis was conducted to evaluate the actual rate of angioedema in the study population and explore differences between patients with and without angioedema.Methods: This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria (CSU). Physicians abstracted angioedema data from medical records, which were compared with patient‐reported data. Patients in the Yes‐angioedema category had angioedema reported in the medical record and a patient‐reported source. For those in the No‐angioedema category, angioedema was reported in neither the medical record nor a patient‐reported source. Those in the Misaligned category had angioedema reported in only one source. Statistical comparisons between Yes‐angioedema and No‐angioedema categories were conducted for measures of CSU activity, health‐related quality of life (HRQoL), productivity and healthcare resource utilization (HCRU). Regression analyses explored the relationship between Dermatology Life Quality Index (DLQI) score and angioedema, adjusting for important covariates.Results: Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were in the Yes‐angioedema, No‐angioedema and Misaligned category, respectively. CSU activity and impact on HRQoL, productivity, and HCRU was greater for Yes‐angioedema patients than No‐angioedema patients. After covariate adjustment, mean DLQI score was significantly higher (indicating worse HRQoL) for patients with angioedema versus no angioedema (9.88 vs 7.27, P < .001). The Misaligned category had similar results with Yes‐angioedema on all outcomes.Conclusions: Angioedema in CSU seems to be under‐reported but has significant negative impacts on HRQoL, daily activities, HCRU and work compared with no angioedema.
Open AccessAngioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU
Background: ASSURE‐CSU revealed differences in physician and patient reporting of angioedema. This post hoc analysis was conducted to evaluate the actual rate of angioedema in the study population and explore differences between patients with and without angioedema.Methods: This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria (CSU). Physicians abstracted angioedema data from medical records, which were compared with patient‐reported data. Patients in the Yes‐angioedema category had angioedema reported in the medical record and a patient‐reported source. For those in the No‐angioedema category, angioedema was reported in neither the medical record nor a patient‐reported source. Those in the Misaligned category had angioedema reported in only one source. Statistical comparisons between Yes‐angioedema and No‐angioedema categories were conducted for measures of CSU activity, health‐related quality of life (HRQoL), productivity and healthcare resource utilization (HCRU). Regression analyses explored the relationship between Dermatology Life Quality Index (DLQI) score and angioedema, adjusting for important covariates.Results: Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were in the Yes‐angioedema, No‐angioedema and Misaligned category, respectively. CSU activity and impact on HRQoL, productivity, and HCRU was greater for Yes‐angioedema patients than No‐angioedema patients. After covariate adjustment, mean DLQI score was significantly higher (indicating worse HRQoL) for patients with angioedema versus no angioedema (9.88 vs 7.27, P < .001). The Misaligned category had similar results with Yes‐angioedema on all outcomes.Conclusions: Angioedema in CSU seems to be under‐reported but has significant negative impacts on HRQoL, daily activities, HCRU and work compared with no angioedema.
- Open Access
- 1 July 2018
- Published by Elsevier in eClinicalMedicine
- Vol. 1, 51-61
Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study
- 1 July 2018
- Published by Elsevier in eClinicalMedicine
- Vol. 1, 51-61
Open AccessImmediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study
- 1 July 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (4) , 1409-1411
Drug-induced aseptic meningitis: A possible T-cell–mediated hypersensitivity
- 1 July 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (4) , 1409-1411
Drug-induced aseptic meningitis: A possible T-cell–mediated hypersensitivity
- 22 June 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (2) , 357-364
Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment
Background Epidermolysis bullosa simplex generalized severe is a genetic disorder caused by mutation in KRT5 or KRT14 genes. Usually considered as a mechanical disease, recent data argue for additional inflammatory mechanisms. Objectives The aim of this study was to assess the inflammation in the skin of patients with EBS. Methods A first immunohistochemical retrospective study was performed on frozen skin samples from 17 EBS‐gen sev patients. A second multicenter prospective study was conducted on 10 patients with severe EBS‐gen sev. Blister fluid and epidermis were processed for immunochemistry analysis and quantitative real time PCR. Cytokine expression was analyzed in blister fluid and compared with controls. Results Histological analysis showed a constant dermal perivascular CD4+ lymphocytes infiltrate in skin biopsies of blister (n=17) as well as in rubbed skin (n=5), an epidermal infiltration of neutrophils and eosinophils in 70% of cases and an increased immunostaining for CXCL9 and CXCL10 in blistering skin. High levels of Th17 cytokines were detected in lesional skin. Three adult patients with EBS‐gen sev were treated with apremilast with a dramatic improvement of skin blistering and good tolerance. Conclusion Our study demonstrates the importance of inflammation in EBS‐gen sev patients and underlines the key role for Th17 cells in its pathogenesis. In addition, this study provides promising new therapeutic approaches for this disabling disorder.
- 22 June 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (2) , 357-364
Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment
Background Epidermolysis bullosa simplex generalized severe is a genetic disorder caused by mutation in KRT5 or KRT14 genes. Usually considered as a mechanical disease, recent data argue for additional inflammatory mechanisms. Objectives The aim of this study was to assess the inflammation in the skin of patients with EBS. Methods A first immunohistochemical retrospective study was performed on frozen skin samples from 17 EBS‐gen sev patients. A second multicenter prospective study was conducted on 10 patients with severe EBS‐gen sev. Blister fluid and epidermis were processed for immunochemistry analysis and quantitative real time PCR. Cytokine expression was analyzed in blister fluid and compared with controls. Results Histological analysis showed a constant dermal perivascular CD4+ lymphocytes infiltrate in skin biopsies of blister (n=17) as well as in rubbed skin (n=5), an epidermal infiltration of neutrophils and eosinophils in 70% of cases and an increased immunostaining for CXCL9 and CXCL10 in blistering skin. High levels of Th17 cytokines were detected in lesional skin. Three adult patients with EBS‐gen sev were treated with apremilast with a dramatic improvement of skin blistering and good tolerance. Conclusion Our study demonstrates the importance of inflammation in EBS‐gen sev patients and underlines the key role for Th17 cells in its pathogenesis. In addition, this study provides promising new therapeutic approaches for this disabling disorder.
- 21 June 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (1) , 56-66
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase IV open‐label SUNRISE study
Background Omalizumab is approved as an add‐on therapy for the treatment of chronic spontaneous urticaria (CSU) in patients with inadequate response to H1‐anti‐histamine treatment. The urticaria control test (UCT) is a reliable, brief tool developed as an alternative to the 7‐day urticaria activity score (UAS7)—the standard for CSU disease activity assessment. Objective This prospective, open‐label, phase IV study evaluated the efficacy and safety of omalizumab in French adult patients with CSU nonresponsive to H1‐antihistamine treatment. Methods Patients (N=136; stratified 1:2 [with angioedema: without angioedema]) received omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks. Study assessments included UCT, UAS7, angioedema activity score and D‐dimer levels (exploratory objective) Results At Week 12, 74.6% of the patients achieved disease control (UCT score ≥12 [primary endpoint]) and 67.7% of patients showed well‐controlled disease (UAS7 ≤6). There was a strong negative correlation between UCT score and UAS7 at Week 12 (Spearman's correlation coefficient −0.839). Mean plasma D‐dimer concentration was elevated at baseline (1002.1 ng/mL) and decreased notably at Week 8 (455 ng/mL). Among the 9 patients with a very high baseline D‐dimer concentration (>3000 ng/mL), 8 were responders (UAS7 ≤6) at Week 12. Conclusions Omalizumab was efficacious in patients with CSU nonresponsive to H1‐antihistamines. The UCT was a reliable tool for disease assessment and the scores correlated well with UAS7. This study does not support the usefulness of D‐dimer to monitor long‐term disease prognosis in adult urticaria, however, it may indicate patients who respond to omalizumab.
- 21 June 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (1) , 56-66
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase IV open‐label SUNRISE study
Background Omalizumab is approved as an add‐on therapy for the treatment of chronic spontaneous urticaria (CSU) in patients with inadequate response to H1‐anti‐histamine treatment. The urticaria control test (UCT) is a reliable, brief tool developed as an alternative to the 7‐day urticaria activity score (UAS7)—the standard for CSU disease activity assessment. Objective This prospective, open‐label, phase IV study evaluated the efficacy and safety of omalizumab in French adult patients with CSU nonresponsive to H1‐antihistamine treatment. Methods Patients (N=136; stratified 1:2 [with angioedema: without angioedema]) received omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks. Study assessments included UCT, UAS7, angioedema activity score and D‐dimer levels (exploratory objective) Results At Week 12, 74.6% of the patients achieved disease control (UCT score ≥12 [primary endpoint]) and 67.7% of patients showed well‐controlled disease (UAS7 ≤6). There was a strong negative correlation between UCT score and UAS7 at Week 12 (Spearman's correlation coefficient −0.839). Mean plasma D‐dimer concentration was elevated at baseline (1002.1 ng/mL) and decreased notably at Week 8 (455 ng/mL). Among the 9 patients with a very high baseline D‐dimer concentration (>3000 ng/mL), 8 were responders (UAS7 ≤6) at Week 12. Conclusions Omalizumab was efficacious in patients with CSU nonresponsive to H1‐antihistamines. The UCT was a reliable tool for disease assessment and the scores correlated well with UAS7. This study does not support the usefulness of D‐dimer to monitor long‐term disease prognosis in adult urticaria, however, it may indicate patients who respond to omalizumab.